KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$30.8 million.

  • Novavax's Net Cash Flow rose 112.14% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.2 million, marking a year-over-year decrease of 261.47%. This contributed to the annual value of -$30.8 million for FY2024, which is 96.00% up from last year.
  • As of FY2024, Novavax's Net Cash Flow stood at -$30.8 million, which was up 96.00% from -$768.3 million recorded in FY2023.
  • Novavax's 5-year Net Cash Flow high stood at $884.8 million for FY2021, and its period low was -$768.3 million during FY2023.
  • In the last 3 years, Novavax's Net Cash Flow had a median value of -$183.9 million in 2022 and averaged -$327.7 million.
  • As far as peak fluctuations go, Novavax's Net Cash Flow soared by 223,000.00% in 2020, and later slumped by 317.71% in 2023.
  • Novavax's Net Cash Flow (Yearly) stood at $564.4 million in 2020, then skyrocketed by 56.76% to $884.8 million in 2021, then crashed by 120.79% to -$183.9 million in 2022, then tumbled by 317.71% to -$768.3 million in 2023, then spiked by 96.00% to -$30.8 million in 2024.